Page 8 - Patrick Wingrove News Today

AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply. AstraZeneca CEO Pascal Soriot in an interview at the Reuters office in New York said the U.S. Centers for Disease Control and Prevention (CDC) had been asking for more of the antibody therapy that was co-developed with French drugmaker Sanofi...

AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply. AstraZeneca CEO Pascal Soriot in an interview at the Reuters office in New York said the U.S. Centers for Disease Control and Prevention (CDC) had been asking for more of the antibody therapy that was co-developed with French drugmaker Sanofi.

Novavax reported revenue of $187 million for the quarter, down from $734.58 million a year ago, but above analysts' expectations of $158.5 million, according to LSEG data. "We've really optimized that U.S. grant opportunity, which was something that was uncertain at the beginning of the year," Novavax CEO John Jacobs said in an interview, adding that the government had shortened the timeline for being able to tap into those funds. The Maryland-based biotech has flagged conc...

COVID-19 vaccine maker Novavax on Thursday reported higher-than-expected revenue for the third quarter, boosted by U.S. government grants to help cover the expense of clinical trials. ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -COVID-19 vaccine maker Novavax on Thursday beat market estimates for quarterly revenue, boosted by U.S.

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight loss treatment, giving the U.S. drugmaker official entry into a lucrative market that has captured Wall Street's enthusiasm this year. The FDA approved tirzepatide for weight loss under the brand name Zepbound. It has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.

The US Federal Trade Commission on Tuesday said it sent letters to medical device companies and drugmakers disputing the accuracy or relevance of 110 patents that could lead to delays in generic competition.

-The U.S. Food and Drug Administration on Wednesday approved Eli Lillys drug for weight loss, giving the U.S. drugmaker official entry into a lucrative market that has captured Wall Streets... -November 08, 2023 at 01:59 pm EST - MarketScreener

The U.S. Federal Trade Commission on Tuesday said it sent notice letters to Abbvie, AstraZeneca, Teva and other drugmakers and medical device companies disputing the accuracy or relevance of more...

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability. The two companies have...